{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:16:20Z","timestamp":1783041380737,"version":"3.54.6"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.prp.2023.154735","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T23:11:20Z","timestamp":1691104280000},"page":"154735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Breast cancer vaccines; A comprehensive and updated review"],"prefix":"10.1016","volume":"249","author":[{"given":"Sulieman Ibraheem Shelash","family":"Al-Hawary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebraheem Abdu Musad","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nodirjon Akhmetovich","family":"Mamajanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"S. Gilmanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashem O.","family":"Alsaab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakeel Ahmed","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Hussien Radie","family":"Alawady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Hashiem","family":"Alsaalamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Jaber","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2023.154735_bib1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00281-022-00966-0","article-title":"Tumor microenvironment antigens","volume":"45","author":"Andersen","year":"2023","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.prp.2023.154735_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10549-022-06562-y","article-title":"The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II\u2013III and metastatic breast cancers.","volume":"194","author":"Anderson","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.prp.2023.154735_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092607","article-title":"The origin and immune recognition of tumor-specific antigens","volume":"12","author":"Apavaloaei","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154735_bib4","doi-asserted-by":"crossref","DOI":"10.1007\/s00005-019-00566-1","article-title":"HER2-positive breast cancer immunotherapy: a focus on vaccine development","volume":"68","author":"Arab","year":"2020","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.prp.2023.154735_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: Global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast (Edinb., Scotl. )"},{"key":"10.1016\/j.prp.2023.154735_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2022.102178","article-title":"HLA variation and antigen presentation in COVID-19 and SARS-CoV-2 infection","volume":"76","author":"Augusto","year":"2022","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib7","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/sj.embor.7401099","article-title":"Interleukin 2: from immunostimulation to immunoregulation and back again","volume":"8","author":"Bachmann","year":"2007","journal-title":"EMBO Rep."},{"key":"10.1016\/j.prp.2023.154735_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115736","article-title":"Hijacked immune cells in the tumor microenvironment: molecular mechanisms of immunosuppression and cues to improve T cell-based immunotherapy of solid tumors","volume":"22","author":"Balta","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2023.154735_bib9","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.prp.2023.154735_bib10","article-title":"Advances in formulation and manufacturing strategies for the delivery of therapeutic proteins and peptides in orally disintegrating dosage forms","volume":"182","author":"Bashir","year":"2023","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"key":"10.1016\/j.prp.2023.154735_bib11","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.prp.2023.154735_bib12","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1128\/CMR.00048-08","article-title":"HLA and infectious diseases","volume":"22","author":"Blackwell","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.prp.2023.154735_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/ar1158","article-title":"Multiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: implications for arthritis and autoimmune diseases","volume":"6","author":"Brunner-Weinzierl","year":"2004","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.prp.2023.154735_bib14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.prp.2023.154735_bib15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13287-022-02719-0","article-title":"Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress","volume":"13","author":"Budi","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.prp.2023.154735_bib16","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.2147\/DDDT.S60328","article-title":"Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies","volume":"9","author":"Chiorean","year":"2015","journal-title":"Drug Des., Dev. Ther."},{"key":"10.1016\/j.prp.2023.154735_bib17","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.prp.2023.154735_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.626463","article-title":"Prophylactic cancer vaccines engineered to elicit specific adaptive immune response","volume":"11","author":"Crews","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2023.154735_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14081854","article-title":"Advances in the immunomodulatory properties of glycoantigens in cancer","volume":"14","author":"da Costa","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154735_bib20","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jconrel.2022.07.036","article-title":"Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches","volume":"349","author":"Davodabadi","year":"2022","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.prp.2023.154735_bib21","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14081671","article-title":"Protein-Based adjuvants for vaccines as immunomodulators of the innate and adaptive immune response: current knowledge, challenges, and future opportunities","volume":"14","author":"D\u00edaz-Dinamarca","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2023.154735_bib23","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1200\/JCO.2009.27.2146","article-title":"Immune regulation of cancer","volume":"28","author":"Disis","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.prp.2023.154735_bib24","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1586\/era.12.147","article-title":"Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade","volume":"12","author":"Emens","year":"2012","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.prp.2023.154735_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.891652","article-title":"Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches","volume":"12","author":"Emran","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2023.154735_bib26","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.3390\/cancers3022554","article-title":"State of the art in tumor antigen and biomarker discovery","volume":"3","author":"Even-Desrumeaux","year":"2011","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154735_bib27","article-title":"Impact of antigen presentation mechanisms on immune response in autoimmune hepatitis","volume":"12","author":"Fasano","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","article-title":"Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis","volume":"5","author":"Feng","year":"2018","journal-title":"Genes Dis."},{"key":"10.1016\/j.prp.2023.154735_bib29","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.3389\/fimmu.2018.03059","article-title":"Dendritic cells and CD8 T cell immunity in tumor microenvironment","volume":"9","author":"Fu","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib30","doi-asserted-by":"crossref","first-page":"12472","DOI":"10.18632\/oncotarget.2998","article-title":"Classification of current anticancer immunotherapies","volume":"5","author":"Galluzzi","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2023.154735_bib31","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1101\/gad.314617.118","article-title":"Roles of the immune system in cancer: from tumor initiation to metastatic progression","volume":"32","author":"Gonzalez","year":"2018","journal-title":"Genes Dev."},{"key":"10.1016\/j.prp.2023.154735_bib32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s12672-022-00491-4","article-title":"Cancer vaccines: past, present and future; a review article","volume":"13","author":"Grimmett","year":"2022","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.prp.2023.154735_bib33","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/s41401-020-0415-5","article-title":"Ex vivo pulsed dendritic cell vaccination against cancer","volume":"41","author":"Gu","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.prp.2023.154735_bib34","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3389\/fonc.2019.01554","article-title":"Reverting Immune Suppression to Enhance Cancer Immunotherapy","volume":"9","author":"Guerrouahen","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2023.154735_bib35","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fimmu.2014.00174","article-title":"How Do CD4(+) T cells detect and eliminate tumor cells that either lack or express mhc class II molecules?","volume":"5","author":"Haabeth","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib36","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.tcb.2014.11.001","article-title":"Balancing the innate immune system in tumor development","volume":"25","author":"Hagerling","year":"2015","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.prp.2023.154735_bib37","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3389\/fimmu.2018.00884","article-title":"Approaches to improve chemically defined synthetic peptide vaccines","volume":"9","author":"Hos","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib38","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.972345","article-title":"Research advance of natural products in tumor immunotherapy","volume":"13","author":"Huo","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib40","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","author":"Iqbal","year":"2014","journal-title":"Mol. Biol. Int. 2014"},{"key":"10.1016\/j.prp.2023.154735_bib41","first-page":"1","article-title":"mRNA vaccination in breast cancer: current progress and future direction","author":"Jiang","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.prp.2023.154735_bib42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00251-018-1095-x","article-title":"Class II MHC antigen processing in immune tolerance and inflammation","volume":"71","author":"Jurewicz","year":"2019","journal-title":"Immunogenetics"},{"key":"10.1016\/j.prp.2023.154735_bib43","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1189\/jlb.1012501","article-title":"TLR agonists: our best frenemy in cancer immunotherapy","volume":"93","author":"Kaczanowska","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.prp.2023.154735_bib44","doi-asserted-by":"crossref","first-page":"1018962","DOI":"10.3389\/fimmu.2022.1018962","article-title":"Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?","volume":"13","author":"Kazemi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.656364","article-title":"Aspects of the tumor microenvironment Involved in immune resistance and drug resistance","volume":"12","author":"Khalaf","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib46","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1245\/s10434-021-11157-w","article-title":"Tumor-infiltrating lymphocytes (TILs) as a biomarker of abscopal effect of cryoablation in breast cancer: a pilot study","volume":"29","author":"Khan","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.prp.2023.154735_bib47","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3389\/fimmu.2020.00940","article-title":"The tumor microenvironment: a milieu hindering and obstructing antitumor immune responses","volume":"11","author":"Labani-Motlagh","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib48","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00262-010-0869-2","article-title":"Anti-HER2 vaccines: new prospects for breast cancer therapy","volume":"59","author":"Ladjemi","year":"2010","journal-title":"Cancer Immunol., Immunother."},{"key":"10.1016\/j.prp.2023.154735_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041164","article-title":"Clinical significance of tumour-infiltrating B lymphocytes (TIL-Bs) in breast cancer: a systematic literature review","volume":"15","author":"Lam","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154735_bib50","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","article-title":"Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors","volume":"38","author":"Leko","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.prp.2023.154735_bib51","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.prp.2023.154735_bib52","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.3389\/fimmu.2019.02191","article-title":"Toll-Like Receptor 7 activation enhances CD8+ T cell effector functions by promoting cellular glycolysis","volume":"10","author":"Li","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib53","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer vaccines as promising immuno-therapeutics: platforms and current progress","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.prp.2023.154735_bib54","doi-asserted-by":"crossref","first-page":"62730","DOI":"10.18632\/oncotarget.17528","article-title":"Driving better and safer HER2-specific CARs for cancer therapy","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2023.154735_bib55","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.7150\/thno.76854","article-title":"Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy","volume":"12","author":"Liu","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.prp.2023.154735_bib56","first-page":"832","article-title":"Decoding cancer's camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade","volume":"3","author":"Lotsberg","year":"2020","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.prp.2023.154735_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13236008","article-title":"Impact of DNA damage response-targeted therapies on the immune response to tumours","volume":"13","author":"Lutfi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154735_bib58","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3390\/cells11020310","article-title":"Myeloid-derived suppressor cells in solid tumors","volume":"11","author":"Ma","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.prp.2023.154735_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cells11020310","article-title":"Myeloid-derived suppressor cells in solid tumors","volume":"11","author":"Ma","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.prp.2023.154735_bib60","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.18693.1","article-title":"Strategies for developing and optimizing cancer vaccines","volume":"8","author":"Maeng","year":"2019","journal-title":"F1000Research"},{"key":"10.1016\/j.prp.2023.154735_bib61","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4137\/CPath.S31563","article-title":"Diversity of breast carcinoma: histological subtypes and clinical relevance","volume":"8","author":"Makki","year":"2015","journal-title":"Clin. Med. Insights Pathol."},{"key":"10.1016\/j.prp.2023.154735_bib62","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1158\/1078-0432.CCR-16-0088","article-title":"Immunotherapy with a HER2-targeting listeria induces HER2-specific immunity and demonstrates potential therapeutic effects in a phase i trial in canine osteosarcomarecombinant HER2\/neu\u2013expressing listeria in osteosarcoma","volume":"22","author":"Mason","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2023.154735_bib63","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5306\/wjco.v8.i2.120","article-title":"Targeted therapies in breast cancer: New challenges to fight against resistance","volume":"8","author":"Masoud","year":"2017","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.prp.2023.154735_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.940052","article-title":"Exhaust the exhausters: Targeting regulatory T cells in the tumor microenvironment","volume":"13","author":"McRitchie","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.783494","article-title":"Breast cancer resistance likelihood and personalized treatment through integrated multiomics","volume":"9","author":"Mehmood","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.prp.2023.154735_bib66","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/1878-0261.13123","article-title":"Recombinant nanobody against MUC1 tandem repeats inhibits growth, invasion, metastasis, and vascularization of spontaneous mouse mammary tumors","volume":"16","author":"Merikhian","year":"2022","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.prp.2023.154735_bib67","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.prp.2023.154735_bib68","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib69","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1002\/cncr.26574","article-title":"Clinical trial results of the HER-2\/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02","volume":"118","author":"Mittendorf","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.prp.2023.154735_bib70","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/08820139.2012.673191","article-title":"Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship","volume":"41","author":"Monu","year":"2012","journal-title":"Immunol. Investig."},{"key":"10.1016\/j.prp.2023.154735_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14133167","article-title":"Immunological landscape of HER-2 positive breast cancer","volume":"14","author":"Moragon","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154735_bib72","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3389\/fimmu.2020.00140","article-title":"Bidirectional crosstalk between cancer stem cells and immune cell subsets","volume":"11","author":"M\u00fcller","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib73","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3389\/fimmu.2020.00140","article-title":"Bidirectional crosstalk between cancer stem cells and immune cell subsets","volume":"11","author":"M\u00fcller","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212339","article-title":"Dendritic cells and cancer immunotherapy: the adjuvant effect","volume":"22","author":"Nava","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2023.154735_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10081249","article-title":"Peptide-based vaccines in clinical phases and new potential therapeutic targets as a new approach for breast cancer: a review","volume":"10","author":"Nicol\u00e1s-Morales","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.prp.2023.154735_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11020453","article-title":"Immunogenicity of different types of adjuvants and nano-adjuvants in veterinary vaccines: a comprehensive review","volume":"11","author":"Nooraei","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.prp.2023.154735_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194958","article-title":"HER2\/neu-based peptide vaccination-pulsed with B-cell epitope induced efficient prophylactic and therapeutic antitumor activities in TUBO breast cancer mice model","volume":"13","author":"Nordin","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154735_bib78","first-page":"143","article-title":"Current progress and challenges in the study of adjuvants for oral vaccines","volume":"37","author":"Ou","year":"2023","journal-title":"BioDrugs Clin. Immunother. Biopharm. Gene Ther."},{"key":"10.1016\/j.prp.2023.154735_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020779","article-title":"Cancer vaccines, treatment of the future: with emphasis on HER2-positive breast cancer","volume":"22","author":"Pallerla","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2023.154735_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413311","article-title":"Immune regulatory processes of the tumor microenvironment under malignant conditions","volume":"22","author":"Pansy","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2023.154735_bib81","doi-asserted-by":"crossref","first-page":"261","DOI":"10.21037\/atm.2016.04.01","article-title":"Harnessing the immune system to improve cancer therapy","volume":"4","author":"Papaioannou","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.prp.2023.154735_bib82","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.prp.2023.154735_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.627932","article-title":"Cancer vaccines, adjuvants, and delivery systems","volume":"12","author":"Paston","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib84","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","article-title":"Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies","volume":"48","author":"Patel","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.prp.2023.154735_bib85","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jha2.356","article-title":"CAR T cell therapy in solid tumors: A review of current clinical trials","volume":"3","author":"Patel","year":"2022","journal-title":"EJHaem"},{"key":"10.1016\/j.prp.2023.154735_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071681","article-title":"Dual effect of immune cells within tumour microenvironment: pro- and anti-tumour effects and their triggers","volume":"14","author":"Pe\u00f1a-Romero","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154735_bib87","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2023.154735_bib88","article-title":"The complex role of regulatory T cells in immunity and aging","volume":"11","author":"Rocamora-Reverte","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib89","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","article-title":"CD28 and CTLA-4 coreceptor expression and signal transduction","volume":"229","author":"Rudd","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.prp.2023.154735_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118343","article-title":"A cross talk between the immunization and edible vaccine: Current challenges and future prospects","volume":"261","author":"Sahoo","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.prp.2023.154735_bib91","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jconrel.2018.01.028","article-title":"Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment","volume":"274","author":"Sau","year":"2018","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"key":"10.1016\/j.prp.2023.154735_bib92","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fimmu.2012.00051","article-title":"Molecular mechanisms of treg-mediated T cell suppression","volume":"3","author":"Schmidt","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib93","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3389\/fimmu.2012.00274","article-title":"Regulatory dendritic cells: there is more than just immune activation","volume":"3","author":"Schmidt","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib94","doi-asserted-by":"crossref","first-page":"15196","DOI":"10.3390\/molecules190915196","article-title":"Small molecule tyrosine kinase inhibitors of ErbB2\/HER2\/Neu in the treatment of aggressive breast cancer","volume":"19","author":"Schroeder","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.prp.2023.154735_bib95","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010138","article-title":"Post-translational modifications in tumor-associated antigens as a platform for novel immuno-oncology therapies","volume":"15","author":"Srivastava","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154735_bib96","article-title":"Tumour virus vaccines: hepatitis B virus and human papillomavirus","volume":"372","author":"Stanley","year":"2017","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B, Biol. Sci."},{"key":"10.1016\/j.prp.2023.154735_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.696791","article-title":"Beyond just peptide antigens: the complex world of peptide-based cancer vaccines","volume":"12","author":"Stephens","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib98","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00262-007-0293-4","article-title":"Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers","volume":"56","author":"Svane","year":"2007","journal-title":"Cancer Immunol., Immunother.: CII"},{"key":"10.1016\/j.prp.2023.154735_bib99","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nri3152","article-title":"Expanding roles for CD4\u207a T cells in immunity to viruses.","volume":"12","author":"Swain","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.prp.2023.154735_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9050535","article-title":"Evolution of cancer vaccines-challenges, achievements, and future directions","volume":"9","author":"Tay","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.prp.2023.154735_bib102","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/1878-0261.12093","article-title":"New insights into the role of EMT in tumor immune escape","volume":"11","author":"Terry","year":"2017","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.prp.2023.154735_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100361","article-title":"Vaccination against Her-2\/neu, with focus on peptide-based vaccines","volume":"7","author":"Tobias","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.prp.2023.154735_bib104","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/vaccines2020323","article-title":"Immune adjuvant effect of molecularly-defined toll-like receptor ligands","volume":"2","author":"Toussi","year":"2014","journal-title":"Vaccines"},{"key":"10.1016\/j.prp.2023.154735_bib105","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1189\/jlb.3RU0316-144R","article-title":"Biological role of granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) on cells of the myeloid lineage","volume":"100","author":"Ushach","year":"2016","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.prp.2023.154735_bib106","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3389\/fimmu.2019.01906","article-title":"CD8(+) T lymphocyte and NK cell network: circuitry in the cytotoxic domain of immunity","volume":"10","author":"Uzhachenko","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib107","article-title":"Amino acids in the development of prodrugs","volume":"23","author":"Vale","year":"2018","journal-title":"Mol. (Basel, Switz. )"},{"key":"10.1016\/j.prp.2023.154735_bib108","article-title":"Interleukin-2 as immunotherapeutic in the autoimmune diseases","volume":"81","author":"Valencia","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.prp.2023.154735_bib109","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1080\/21645515.2021.1911204","article-title":"COVID-19 vaccine platforms: Delivering on a promise?","volume":"17","author":"Verdecia","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.prp.2023.154735_bib110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12105","article-title":"Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy","volume":"1284","author":"Vesely","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.prp.2023.154735_bib111","first-page":"232","article-title":"Cell-mediated immune resistance in cancer","volume":"3","author":"Wang","year":"2020","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.prp.2023.154735_bib112","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners","volume":"40","author":"Wojtukiewicz","year":"2021","journal-title":"Cancer Metastas-.-. Rev."},{"key":"10.1016\/j.prp.2023.154735_bib113","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.prp.2023.154735_bib114","doi-asserted-by":"crossref","first-page":"1097983","DOI":"10.3389\/fonc.2023.1097983","article-title":"Immunotherapy for HER-2 positive breast cancer","volume":"13","author":"Yang","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2023.154735_bib115","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrc.2016.154","article-title":"Targeting neoantigens to augment antitumour immunity","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2023.154735_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.771201","article-title":"Targeting innate immunity in breast cancer therapy: a narrative review","volume":"12","author":"Ye","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib117","doi-asserted-by":"crossref","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412","article-title":"Biological subtypes of breast cancer: Prognostic and therapeutic implications","volume":"5","author":"Yersal","year":"2014","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.prp.2023.154735_bib118","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res.: BCR"},{"key":"10.1016\/j.prp.2023.154735_bib119","doi-asserted-by":"crossref","first-page":"7807","DOI":"10.7150\/thno.37194","article-title":"Peptide-based materials for cancer immunotherapy","volume":"9","author":"Zhang","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.prp.2023.154735_bib120","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.molimm.2022.02.015","article-title":"Natural killer cell dysfunction in cancer and new strategies to utilize NK cell potential for cancer immunotherapy","volume":"144","author":"Zhang","year":"2022","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib121","first-page":"491","article-title":"Engineered tumor cell-derived vaccines against cancer: The art of combating poison with poison","volume":"22","author":"Zhang","year":"2023","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.prp.2023.154735_bib122","article-title":"Neoantigen: a new breakthrough in tumor immunotherapy","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2023.154735_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.762796","article-title":"Clinical and immunological effects of p53-targeting vaccines","volume":"9","author":"Zhou","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.prp.2023.154735_bib124","article-title":"Breast cancer vaccines: disappointing or promising?","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Immunol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823004351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823004351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T07:06:09Z","timestamp":1759734369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033823004351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":124,"alternative-id":["S0344033823004351"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2023.154735","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breast cancer vaccines; A comprehensive and updated review","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2023.154735","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"154735"}}